Currently approved options include orlistat, naltrexone/bupropion (Mysimba note that NHS commissioning of this medicine varies by local area), and semaglutide (Wegovy), which has a NICE technology appraisal recommendation for weight management
Eli Lilly and Company 's Retatrutide Shows Up to 28% Weight Loss in Phase-3 Study Eli Lilly reported promising Phase-3 results for #retatrutide, with the triple agonist therapy demonstrating up to 28% weight loss, marking a major milestone in next-generation obesity treatment innovation
This article covers how Retatrutide works, its trial results, and its potential for obesity management
Beyond chemotherapy combinations, investigators are examining Retatrutide's interaction with immunotherapy agents
Are you sensitive to appetite changes or rebound fatigue
Clean the area beforehand